1760 — Panion & BF Biotech Income Statement
0.000.00%
Last trade - 00:00
- TWD7.56bn
- TWD7.73bn
- TWD1.88bn
- 72
- 15
- 36
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,574 | 1,569 | 1,901 | 2,399 | 1,882 |
Cost of Revenue | |||||
Gross Profit | 864 | 814 | 912 | 1,319 | 974 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,350 | 1,464 | 1,736 | 1,985 | 1,725 |
Operating Profit | 224 | 105 | 165 | 414 | 157 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 226 | 89.4 | 183 | 333 | 169 |
Provision for Income Taxes | |||||
Net Income After Taxes | 161 | 27.9 | 104 | 182 | 77.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 161 | 27.9 | 104 | 182 | 77.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 161 | 27.9 | 104 | 182 | 77.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.14 | 0.356 | 1.32 | 2.08 | 0.902 |
Dividends per Share |